Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Insmed (INSM) PT Raised to $58 at UBS
May 29, 2024 5:37 AM EDTUBS analyst Trung Huynh raised the price target on Insmed (NASDAQ: INSM) to $58.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "Management believes from now through the regulatory review process, the path is noncontroversial given the strength of data presented... More
Insmed (INSM) PT Raised to $68 at Truist Securities
May 29, 2024 5:30 AM EDTTruist Securities analyst Nicole Germino raised the price target on Insmed (NASDAQ: INSM) to $68.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "With greater confidence into brensocatib potential approval following positive ASPEN results today and supported by our KOL call last... More
Insmed (INSM) PT Raised to $54 at Wolfe Research
May 29, 2024 5:25 AM EDTWolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $54.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "How to think about stock valuation, even assuming a capital raise? The previous stock in the mid-$20s implied POS... More
Insmed (INSM) PT Raised to $60 at Morgan Stanley
May 28, 2024 2:37 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $60.00 (from $43.00) while maintaining a Overweight rating.
The analyst comments "With clear positive results from the ASPEN topline data, questions on the conference call focused more on the potential commercial... More
Goldman Sachs Reiterates Buy Rating on Insmed (INSM)
May 28, 2024 1:27 PM EDTGoldman Sachs analyst Andrea Tan reiterated a Buy rating and $74.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "INSM announced positive topline ASPEN data in patients with non-CF bronchiectasis where brensocatib treatment resulted in statistically significant and clinically meaningful reductions in the frequency of pulmonary exacerbations (21.1%/19.4% for 10mg/25mg, respectively) along with benefit on various... More
JPMorgan Reiterates Overweight Rating on Insmed (INSM)
May 28, 2024 10:45 AM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $36.00 price target on Insmed (NASDAQ: INSM)
The analyst comments "This morning Insmeds ASPEN study hit a home run scenario. Both the 10mg and 25mg doses reached statistical significance with p-values less than 0.01... More
Stifel Reiterates Buy Rating on Insmed (INSM)
May 28, 2024 7:54 AM EDTStifel analyst Stephen D. Willey reiterated a Buy rating and $35.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "This mornings top-line disclosure of P3 ASPEN data represents, in our opinion, a best-case scenario for INSM shares with top-line data not only supportive of what we (conservatively) believe to represent a $2.5B+ commercial opportunity in NCFBE, but also improving visibility into future label expansion opportunities such as CRSsNP (P2 ongoing) and HS (P2 now likely to initiate). We believe todays disclosure also eliminates all balance sheet and capital structure concerns... More
Evercore ISI Reiterates Outperform Rating on Insmed (INSM)
May 28, 2024 7:36 AM EDTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $42.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "Highly anticipated ASPEN data is the best-case scenario for INSM with both doses of brensocatib reaching the primary & multiple secondary endpoints.... More
Morgan Stanley Reiterates Overweight Rating on Insmed (INSM)
May 28, 2024 7:16 AM EDTMorgan Stanley analyst Jeffrey Hung reiterated an Overweight rating and $43.00 price target on Insmed (NASDAQ: INSM).
The analyst comments "Positive topline results from the brensocatib Phase 3 ASPEN study for bronchiectasis are a clear win, unlocking massive value for Insmed. Both 10mg and 25mg doses showed statistically significant 19-21% reductions in annualized rate of pulmonary exacerbations.... More
